Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders.

  title={Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders.},
  author={Joshua D Lee and Peter D Friedmann and Timothy W. Kinlock and Edward V. Nunes and Tamara Boney and Randall A Hoskinson and Donna Wilson and Ryan McDonald and John Rotrosen and Marc N. Gourevitch and Michael Gordon and Marc J Fishman and Donna T Chen and Richard J Bonnie and James Cornish and Sean M Murphy and Charles P O'brien},
  journal={The New England journal of medicine},
  volume={374 13},
BACKGROUND Extended-release naltrexone, a sustained-release monthly injectable formulation of the full mu-opioid receptor antagonist, is effective for the prevention of relapse to opioid dependence. Data supporting its effectiveness in U.S. criminal justice populations are limited. METHODS In this five-site, open-label, randomized trial, we compared a 24-week course of extended-release naltrexone (Vivitrol) with usual treatment, consisting of brief counseling and referrals for community… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 30 extracted citations


Publications referenced by this paper.
Showing 1-10 of 43 references

Efficacy and tolerability

  • J C.Garbutt, H R.Kranzler, S S.O’Malley, D R.Gastfriend, H M.Pettinati, B LSilverman
  • JAMA
  • 2013
2 Excerpts


  • UNODC. World Drug Report 2010 United Nations Publication, Sales No. E.10.XI.13. 2010. Available at
  • unodc.org/documents/wdr/WDR_2010/World_Drug_…
  • 2012
1 Excerpt

Similar Papers

Loading similar papers…